Loading News...
Back to Dashboard

Moderna, Inc. (MRNA)

Real-time intraday values

Market Overview

From:
To:
MRNA Intraday
No data available
SymbolMRNA
IPO DateDec 7, 2018
CEOMr. Stéphane Bancel M.B.A.
Full Time Employees4.7k
SectorHealthcare
IndustryBiotechnology
CountryUnited States
ExchangeNasdaqGS
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Performance
PeriodReturn %Value Change
1 Day
+6.25%
+3.26 US$
5 Days
+11.58%
+5.75 US$
1 Month
+12.95%
+6.35 US$
6 Months
+81.55%
+24.88 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of MRNA...

Key Statistics
Market Cap
21.98B
P/E Ratio
N/A
Div Yield
N/A
52W High
$59.55
52W Low
$22.28

Analyst Consensus

ConsensusHold
Bullish313.0%
Neutral1669.6%
Bearish417.4%

52W Analyst Price Targets

Min Target
$21.00
Max Target
$69.00
Current$55.39
Avg Target$43.30

Analyst Recommendations

Target Price:$43.30($21.00 - $69.00)
FirmRatingTarget PriceUpside PotentialDate
B of A SecuritiesUnderperform$34.00-38.62%6/8/2026
UBSNeutral$45.00-18.76%5/4/2026
Goldman SachsNeutral$49.00-11.54%5/4/2026
Evercore ISI GroupIn-Line$50.00-9.73%5/4/2026
RBC CapitalSector Perform$38.00-31.40%5/4/2026
BarclaysEqual-Weight$48.00-13.34%4/2/2026
Piper SandlerOverweight$69.00+24.57%2/23/2026
Goldman SachsNeutral$41.00-25.98%2/17/2026
RBC CapitalSector Perform$30.00-45.84%2/17/2026
Evercore ISI GroupIn-Line$35.00-36.81%2/17/2026
Community Thoughts

Share your analysis and sentiment on MRNA

Join the community to share your analysis